Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended January 31, 2002 (First Quarter of Fiscal 2002)
Business Overview: Cooper develops, manufactures, and markets healthcare products through two primary segments: CooperVision (CVI), specializing in contact lenses, and CooperSurgical (CSI), focusing on gynecological diagnostic products and surgical instruments.
Key Financial Metrics
| Metric (in thousands) | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $58,112 | $49,976 |
| Gross Profit | $37,487 | $33,186 |
| Gross Margin | 65% | 66% |
| Operating Income | $13,107 | $9,665 |
| Net Income | $9,405 | $6,309 |
| Diluted EPS | $0.61 | $0.43 |
| Operating Cash Flow | $4,168 | $2,450 |
| Cash and Equivalents (End of Period) | $4,867 | $11,980 |
| Total Debt (Short + Long Term) | $63,916 | $68,799 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% to $58.1 million, driven by 16% growth in CVI and 18% growth in CSI. International revenue for CVI surged 41%.
- Profitability: Operating income rose 36% to $13.1 million, and Net Income increased 49% to $9.4 million. Diluted EPS grew 42%.
- Accounting Change: Adoption of SFAS 142 eliminated goodwill amortization. Amortization expense dropped 75% to $308,000 from $1.22 million in the prior year.
- One-Time Gains: Other income included a $1.0 million gain from the sale of Quidel stock, compared to a $719,000 gain from a stock exchange in the prior year.
- Debt Reduction: Total debt decreased by approximately $4.9 million due to repayments, though short-term debt increased significantly to fund acquisitions.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Acquisitions: On February 28, 2002, Cooper acquired the contact lens business of Biocompatibles International plc for approximately $97 million (cash and notes). CooperSurgical also agreed to acquire the bone densitometry business of Norland Medical Systems for up to $12 million.
- Liquidity: Management expects cash on hand and operating cash flow to fund operations and smaller acquisitions. An expanded bank credit facility is being negotiated for completion in early May 2002 to repay notes issued for the Biocompatibles acquisition.
- Tax Strategy: A global tax plan is expected to extend cash flow benefits of net operating loss carryforwards through 2004, with actual cash tax payments averaging less than 5% of pretax profits during that period.
Risks and Contingencies
- Litigation: Wesley Jessen Corporation (WJ) has sued CooperVision alleging patent infringement regarding "Frequency Colors" opaque contact lenses in the U.S., England, and France. Revenue from disputed products was approximately $1.2 million in Q1 2002. Cooper intends to vigorously defend the actions.
- Market Risk: Exposure to foreign exchange fluctuations (primarily British pound sterling) and interest rate changes on variable-rate debt.
- Integration: Risks associated with integrating recent acquisitions (Biocompatibles, Norland) and potential delays or costs.
Investor Verification Checklist
- Acquisition Financing: Verify the terms and repayment schedule of the $44 million promissory notes issued to Biocompatibles and the status of the expanded credit facility negotiation.
- Litigation Exposure: Monitor the status of the Wesley Jessen patent infringement lawsuits and potential impact on the "Frequency Colors" product line revenue.
- Goodwill Impairment: Review the results of the SFAS 142 goodwill impairment testing expected to be completed by the end of the second fiscal quarter.
- Cash Position: Confirm the sustainability of the $4.9 million cash balance given the recent $97 million acquisition and ongoing capital expenditures.
- Margin Trends: Assess the long-term impact of increased international sales and retail channel expansion on gross margins, which management expects to decline slightly.